Regulus Therapeutics, Inc.(NASDAQ : RGLS)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
Health Technology » Pharmaceuticals Other
|SAVA||Cassava Sciences, Inc.||12.23%||87.04||0.0%||$239.29m|
|HZNP||Horizon Therapeutics Plc||0.64%||95.03||5.5%||$179.97m|
|VRX||Valeant Pharmaceuticals International, Inc.||1.75%||29.59||14.1%||$174.11m|
|JAZZ||Jazz Pharmaceuticals Plc||1.11%||178.95||2.2%||$124.11m|
|SAGE||SAGE Therapeutics, Inc.||1.56%||57.26||7.6%||$75.58m|
|UTHR||United Therapeutics Corp.||0.11%||174.83||14.0%||$65.04m|
|BHC||Bausch Health Cos., Inc.||1.75%||29.59||0.0%||$57.60m|
|PRGO||Perrigo Co. Plc||0.52%||46.27||6.9%||$56.22m|
|PCRX||Pacira Biosciences, Inc.||1.06%||61.03||9.9%||$29.79m|
|IRWD||Ironwood Pharmaceuticals, Inc.||1.82%||12.63||9.6%||$24.79m|
|RVMD||Revolution Medicines, Inc.||1.89%||33.47||0.0%||$24.73m|
|AXSM||Axsome Therapeutics, Inc.||0.72%||70.18||1.9%||$24.14m|
Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded on September 5, 2007 and is headquartered in San Diego, CA.